Found 184 articles
Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the appointment of Ian Sanderson, MBA, as Chief Financial Officer.
9/17/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Lightstone Ventures recently announced the closing of Lightstone Ventures III, securing $375 million to invest in early-stage firms that develop high-impact technologies that can change lives.
Nimbus Therapeutics Announces First Patient Dosed in Phase 2b Study of Oral Allosteric TYK2 Inhibitor in Patients with Moderate to Severe Psoriasis
Nimbus Therapeutics today announced dosing of patients in the Phase 2b study of the company’s oral allosteric TYK2 inhibitor.
Nimbus Therapeutics and Schrödinger Extend Longstanding Collaboration to Discover Novel Therapeutics for Select Targets
Nimbus Therapeutics today announced the extension of its collaboration with Schrödinger, Inc. to discover and design small molecule therapeutics for a number of high-value targets using cutting-edge structure-based drug design approaches.
The drug modeling software market was valued at US$ 6,205.22 million in 2019 and is projected to reach US$ 11,299.85 million by 2027; it is expected to grow at a CAGR of 8.1% from 2020 to 2027.
7/23/2021Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, announced key appointments to its science leadership: David Proia, Ph.D., as Vice President, Oncology; Menachem Fromer, Ph.D., as Head of Data Science; and Sarah Knutson, Ph.D., as Senior Director, Early Discovery.
Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs
Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the closing of a $105 million private financing round.
Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced it has appointed Anne McGeorge, M.S., CPA, to its Board of Directors, and as Audit Committee Chair.
Nimbus Therapeutics Expands Development Team to Advance Multiple Portfolio Programs Through Clinical Testing
- Key hires in clinical and CMC augment Nimbus’ in-house capabilities as a development-stage biotech -
Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor
Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the presentation of data from the company’s HPK1 inhibitor program in a poster at the AACR Annual Meeting held virtually April 10-15, 2021.
Industry veteran will draw on unique mix of scientific and business acumen to support Company's efforts to combat cancer with growing portfolio of novel myeloid-targeting therapies
It will evaluate about 440 patients and the treatments’ effect on liver fibrosis improvement and NASH resolution.
Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2020 and Provides Outlook for 2021
Total revenue of $108.1 million in 2020, up 26 percent year-over-year Software revenue of $92.5 million in 2020, up 39 percent year-over-year Strong financial position enables continued investment in advancing the science underlying Schrödinger’s computational platform Internal pipeline progressing, with plans to submit investigational new drug applications in 2022 Conference call today, Thursday, March 4, at 8:30 a.m. ET
Jnana Therapeutics Appoints Dr. Annie Chen to Board of Directors and Dr. Katalin Susztak to Scientific Advisory Board
Jnana Therapeutics , a biotechnology company targeting the solute carrier (SLC) family of metabolite transporters to treat underserved diseases, today announced the appointment of two experienced scientific and clinical leaders to the company’s boards. Annie C. Chen, MD, MPH, Chief Medical Officer of Nimbus Therape
Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases
Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures.
SciNeuro Pharmaceuticals, based in Shanghai, China, launched with a $100 million Series A financing.
Lilly Asia Ventures Fund and Arch Venture Partners co-lead $100M Series A financing to advance the establishment of a robust and innovative CNS pipeline
Venture capital firm SR One, founded in 1985 as the venture capital arm of pharma giant GlaxoSmithKline, completed its spinout from its parent company and closed its first independent fun at $500 million.